NewBridge Pharmaceuticals, Eisai sales and marketing update

Eisai and NewBridge partnered to commercialize Eisai's Halaven eribulin in the Middle East. The synthetic analog of halichondrin B is approved to treat locally advanced or metastatic breast cancer th...